Abiopharma

🔍 Prasad Raju (Executive)

Company: CRISPR Therapeutics AG (CRSP)

Report Date: 2026-01-06

Detailed Transactions and Holdings:

• Acquired 23,361 shares of Common Shares at $45.15 per share (Direct)
  Date: 2026-01-06 | Code: M | equity_swap_involved: false | shares_owned_after: 30,128.00 | transaction_form_type: 4
• Acquired 6,339 shares of Common Shares at $44.31 per share (Direct)
  Date: 2026-01-06 | Code: M | equity_swap_involved: false | shares_owned_after: 36,467.00 | transaction_form_type: 4
• Sold 18,933 shares of Common Shares at $60.1799 per share (Direct)
  Date: 2026-01-06 | Code: S | equity_swap_involved: false | shares_owned_after: 17,534.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 5,004 shares of Common Shares at $60.0 per share (Direct)
  Date: 2026-01-06 | Code: S | equity_swap_involved: false | shares_owned_after: 12,530.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 5,763 shares of Common Shares at $60.2134 per share (Direct)
  Date: 2026-01-06 | Code: S | equity_swap_involved: false | shares_owned_after: 6,767.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 23,361 shares of Stock Option (Right to Buy) at $45.15 per share (Derivative)
  Date: 2026-01-06 | Code: M | Expires: 2033-03-14 | equity_swap_involved: false | shares_owned_after: 76,639.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 6,339 shares of Stock Option (Right to Buy) at $44.31 per share (Derivative)
  Date: 2026-01-06 | Code: M | Expires: 2033-10-13 | equity_swap_involved: false | shares_owned_after: 7,493.00 | transaction_form_type: 4 | Footnotes: F5

Footnotes:

• F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.0000 to $60.7300, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.0000 to $60.4800, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
• F4: This option was granted on March 14, 2023 with respect to 100,000 Common Shares, with 25% of the shares vesting on March 14, 2024 and the remaining shares vesting on each monthly anniversary thereafter for a period of 36 months.
• F5: This option was granted on October 13, 2023 with respect to 13,832 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 13, 2023.